Vivanza Biosciences Intrinsic Value
Vivanza Biosciences (VIVANZA) median intrinsic value is ₹4.40 from 3 valuation models (range ₹4–₹4), vs current price ₹1.76 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Check VIVANZA market capitalization to track the company's total market size over time.
VIVANZA Valuation Methods Summary — DCF, Graham Number & P/E
Vivanza Biosciences intrinsic value across 3 models vs current price ₹1.76 — upside/downside and value range per method. For current market price and key ratios, visit Vivanza Biosciences stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹4.40 | ₹3.96 - ₹4.84 | +150.0% | Book Value/Share: ₹10.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3.52 | ₹3.17 - ₹3.87 | +100.0% | Revenue/Share: ₹60.00, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹4.40 | ₹3.52 - ₹5.28 | +150.0% | CF Growth: 5.0%, Discount: 15% |
VIVANZA Intrinsic Value vs Market Price — All Valuation Models
Vivanza Biosciences fair value range ₹4–₹4 vs current market price ₹1.76 across 3 valuation models. See VIVANZA price book multiple to compare market price against book value per share.
VIVANZA Intrinsic Value Analysis — Undervalued or Overvalued?
Vivanza Biosciences median intrinsic value ₹4.40, current price ₹1.76 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of VIVANZA?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Vivanza Biosciences (VIVANZA) is ₹4.40 (median value). With the current market price of ₹1.76, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹3.52 to ₹4.40, indicating ₹3.52 - ₹4.40.
Is VIVANZA undervalued or overvalued?
Based on our multi-method analysis, Vivanza Biosciences (VIVANZA) appears to be trading below calculated value by approximately 150.0%.
VIVANZA Financial Health — Key Ratios vs Industry Benchmarks
Vivanza Biosciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 19.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | -4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.09x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
VIVANZA Cash Flow Quality — Operating & Free Cash Flow
Vivanza Biosciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |